Acquisition of Yellow Jersey Therapeutics by Johnson & Johnson

Tuesday, 28 May 2024, 08:48

Learn about the recent acquisition news involving Numab Therapeutics and Johnson & Johnson. The acquisition includes the rights to NM26, a bi-specific antibody for treating Atopic Dermatitis. Johnson & Johnson's move to acquire Yellow Jersey Therapeutics signals a strategic focus on expanding their pharmaceutical portfolio in the dermatology segment.

https://store.livarava.com/5c9b1481-1ce8-11ef-a3db-9d5fa15a64d8.jpg — Acquisition of Yellow Jersey Therapeutics by Johnson & Johnson

Numab Therapeutics Announcement

Numab Therapeutics recently made a significant announcement regarding the acquisition of its wholly-owned subsidiary, Yellow Jersey Therapeutics, by Johnson & Johnson. This acquisition includes the rights to NM26, a bi-specific antibody targeted for the treatment of Atopic Dermatitis.

Strategic Move by Johnson & Johnson

Johnson & Johnson is strategically expanding its presence in the pharmaceutical market by acquiring Yellow Jersey Therapeutics and gaining access to the promising NM26 antibody. This move indicates the company's commitment to advancing healthcare solutions, particularly in the dermatology sector.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.